Project Grant HT94252510980
Award Date 11/1/25
Completion Date 10/31/28
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
- The University of California, Davis was awarded a $1,446,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on "THERAPEUTIC TARGETING OF A NOVEL TUMOR-INTRINSIC SIGNALING PATHWAY FOR LETHAL PROSTATE CANCER." The award period is from August 1, 2023 to July 31, 2026. UC Davis will leverage its expertise in medical research to investigate potential medical solutions relevant to the...
- This federal Project Grant award, totaling $1,163,420.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the University of California, Davis. The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The research aims to investigate functional and phenotypic metabolic transitions governing disease state in clear cell renal cell...
- This Project Grant award of $1,801,179.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of California, Davis (UC Davis) focused on the "Contribution of Bone Mass and Fracture to Bone Metastasis in Prostate Cancer". The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative medical solutions to address...
- The University of California, Davis was awarded a $1,446,009 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to target CD200/CD200R signaling as a novel strategy for treating therapy-resistant prostate cancer. The grant, awarded July 1, 2023 and set to be completed by June 30, 2026, will support research into medical solutions for prostate cancer that remains unresponsive to standard treatments by...
- This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period...
- This Project Grant award of $636,285 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of California, Davis (UC Davis) on "TRIPLE AKR1C3/COX2/SEH INHIBITION FOR THE TREATMENT OF LETHAL PROSTATE CANCER." The funding will be used over a 3-year period from September 2023 to August 2026 to conduct basic, translational, and clinical research aimed at developing new treatments for prostate cancer, a key health...
- This federal Project Grant award of $481,056, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of California, Davis to investigate the role of the protein ARHGEF2 in promoting neural lineage plasticity and treatment resistance in advanced prostate cancer. The research aims to transform healthcare for military service members, veterans, and the general public by advancing the...
- The University of California, Davis was awarded a $1,177,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research to target a key tumor plasticity driver in lethal prostate cancer. Through August 2021 to July 2024, UC Davis researchers will investigate medical solutions for prostate cancer on the cellular level with the aim of transforming patient care and outcomes. The...
- The University of California, Davis (UC Davis) was awarded a $644,000 Project Grant under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on a novel "PLZ4-Targeting Ultra-Small DM1 Nanoconjugate for Bladder Cancer Therapy". The project will run from June 1, 2025 to May 31, 2027. As a prominent public research university, UC Davis has extensive capabilities in biomedical research and has established itself as a key...
- This federal Project Grant award of $1,298,836.00 from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) supports advanced biomedical research at the University of California, Davis (UC Davis) aimed at transforming healthcare for military service members, veterans, and the public. The purpose of this award is to conduct research on toxic products of combustion in burn and smoke inhalation injuries. This award modifies the previous terms by removing the...